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Aims To investigate the efﬁcacy and outcome of emergency percutaneous coronary
interventions (PCI) in patients with stent thrombosis.
Methods and results Between 1995 and 2003, 6058 patients underwent bare-metal
stent implantation, of which 95 (1.6%) patients suffered from stent thrombosis. The
timing of stent thrombosis was acute in 10 (11%), subacute in 61 (64%), and late in
24 (25%) patients. Procedural and clinical outcomes of emergency PCI for treatment
of stent thrombosis were investigated. Emergency PCI was successful in 86 (91%), com-
plicated by death in 2 (2%), and coronary artery bypass grafting in 2 (2%) patients.
Myocardial infarction occurred in 77 (81%) patients with a peak creatine kinase
level of 1466+ 1570 U/L. Left ventricular ejection fraction declined from
0.54+ 0.19 prior to 0.48+ 0.16 (P, 0.05) at the time of stent thrombosis after
emergency PCI. A 6 month major adverse clinical events comprised death (11%), rein-
farction (16%), and recurrent stent thrombosis (12%) after emergency PCI. Multivari-
able logistic regression analysis identiﬁed the achievement of TIMI 3 ﬂow (OR ¼ 0.1,
CI 95% 0.01–0.54, P, 0.001) and diameter stenosis ,50% (OR ¼ 0.06, CI 95%
0.01–0.32, P, 0.001) during emergency PCI to be independently associated with a
reduced risk of cardiac death. Recurrent stent thrombosis was independently pre-
dicted by the omission of abciximab (OR ¼ 4.3, CI 95% 1.1–17.5).
Conclusion Emergency PCI for treatment of stent thrombosis effectively restores
vessel patency and ﬂow. Patients presenting with stent thrombosis are at risk for
recurrent myocardial infarction and recurrent stent thrombosis.
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Introduction
Stents have improved the safety and efﬁcacy of percuta-
neous coronary interventions (PCI) by reducing abrupt or
threatened vessel closure1,2 and by reducing restenosis3,4
compared with conventional balloon angioplasty. In
addition, coronary vasomotion has been found intact after
stent implantation5 and long-term clinical and angiographic
follow-up have attested to the durability of their action.6
Notwithstanding, coronary stent thrombosis has
remained a serious complication of PCI.7 Although early
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aggressive anticoagulation schemes were associated with
unacceptably high rates of stent thrombosis and bleeding
complications,3,4,8 the advent of dual antiplatelet therapy
had salutary effects on both adverse events.7,9–12 Despite
dual antiplatelet therapy, stent thrombosis persists at
a rate of 0.5–2%13–16 in elective cases, and up to 6%
in patients with acute coronary syndromes.15,17
Furthermore, longer stent length, number of implanted
stents,13,15 stent malapposition,18 residual dissections,13,19
reduced TIMI ﬂow,19 gene polymorphisms,20 and resistance
to the antiplatelet effects of acetylsalicylic acid (ASA)21 and
potentially thienopyridines22,23 have been reported to
increase the risk for stent thrombosis.
The clinical sequelae of stent thrombosis including
death and myocardial infarction are grave13,15 and
demand aggressive therapeutic interventions. Although
emergency PCI is commonly employed, the efﬁcacy of
the procedure and long-term outcome of patients in
this setting is not well established. Previous studies
reported only a limited efﬁcacy of PCI and intracoronary
ﬁbrinolysis,24 but a possibly favourable effect of the
glycoprotein IIb/IIIa antagonist abciximab for the treat-
ment of stent thrombosis.25 The purpose of the present
study was to investigate the efﬁcacy of emergency PCI
in patients with stent thrombosis and to identify predic-
tors of adverse outcome in the largest consecutive
patient population reported to date.
Methods
Study design
All patients presenting with stent thrombosis undergoing emer-
gency PCI between 1995 and 2003 were included in the analysis.
Patients with stent thrombosis were identiﬁed in our database,
which is kept abreast by active follow-up. Medical records and
angiograms of all patients with stent thrombosis were analysed.
The study, which complied with the Declaration of Helsinki, was
approved by the local ethics committee, and written informed
consent was obtained from patients included in the study.
Patients had to fulﬁl clinical and angiographic criteria of ST.
Clinical criteria consisted of the acute onset of chest pain
persisting for .15 min and/or accompanied by ST segment
elevation or depression of at least 1 mm in two contiguous
leads in the distribution of the target vessel. All patients with
the clinical suspicion of stent thrombosis underwent immedi-
ate coronary angiography to conﬁrm the diagnosis followed by
PCI. Angiographic criteria of stent thrombosis consisted of
partial or complete occlusion within the previously implanted
stent with evidence of fresh thrombus. Only patients with angio-
graphically conﬁrmed stent thrombosis were included in the
present study. The intervention in the setting of stent thrombosis
was termed emergency PCI to clearly distinguish it from primary
PCI in the setting of acute ST segment elevation myocardial
infarction.
Emergency PCI for treatment of
stent thrombosis
All patients presenting with stent thrombosis were immediately
brought to the catheterization laboratory. ASA was administered
intravenously (250–500 mg) in the exceptional patient not taking
ASA (100 mg). The use of a glycoprotein IIb/IIIa antagonist was
left to the discretion of the operator. Intravenous weight-
adjusted heparin was used to achieve an activated clotting
time 250 s. Recanalization of the occluded target vessel was
performed in most cases with a recanalization wire and a low-
proﬁle balloon. Additional stent implantation was performed if
residual dissections or a signiﬁcant (.50%, visually estimated)
stenosis was present. Distal embolization protection devices
were not routinely used during this period. The post-procedural
treatment consisted of dual antiplatelet therapy with daily ASA
and a thienopyridine for at least 1 month.
Deﬁnitions, clinical follow-up, and clinical
endpoints
Stent thrombosis was deﬁned as sudden onset of typical chest pain
with electrocardiographic changes, indicating acute ischaemia in
the distribution of the target vessel. Acute stent thrombosis was
deﬁned as occurring during the 24 h after the intervention, sub-
acute between 1 and 30 days, and late beyond 30 days after the
intervention. Stent thrombosis was angiographically conﬁrmed
in all patients included in the present study. Angiographic deﬁ-
nition of stent thrombosis was a complete or partial occlusion
within the stented segment with evidence of thrombus.
Procedural success was deﬁned as normal ﬂow (TIMI 3) with a ste-
nosis ,50%. Quantitative coronary analysis of the target vessel
was performed in all cases on the angiogram of the index pro-
cedure and the angiogram at the time of stent thrombosis.
Major adverse clinical eventswere assessed at the time of hospital
discharge and 6 months after the intervention using a question-
naire. Long-term follow-up was completed in 98% of cases.
Two patients had moved abroad and could not be located.
Myocardial infarction was deﬁned as an elevation of creatine
kinase twice the upper limit of normal value and three times
the upper limit of normal value of CK-MB fraction.
Statistical analysis
Continuous data were expressed as mean+ standard deviation.
Continuous variables were compared using the Student’s t-test,
and paired categorical variables were compared using the test
by McNemar. The data analysed were normally distributed.
Survival estimates were computed using the Kaplan–Meier
method and compared with a log-rank test. Predictors of
cardiac death and predictors of recurrent stent thrombosis at 6
months follow-up were assessed with a multivariable logistic
regression analysis. First, an univariate analysis was performed
with the following variables: age .65 years, gender, ejection
fraction ,40%, TIMI 3 ﬂow before and after the intervention,
use of glycoprotein IIb/IIIa (abciximab and tiroﬁban) antagonists,
residual dissection, stenosis ,50% post-PCI, diabetes, and
smoking. Then, variables with a P-value ,0.15 were entered
into the multivariable model. The measure of predictive
accuracy was assessed by receiver operating characteristic
curve with an area of 0.770. A two-tailed P-value of ,0.05
was considered signiﬁcant. All statistical analyses were
performed with the SPSS 10.0.5 program, Chicago, IL, USA.
Results
Incidence of stent thrombosis
Between November 1995 and March 2003, 95 (1.6%) of
6058 patients treated at our institution with bare-metal
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stents suffered from stent thrombosis. Stent thrombosis
occurred after a median of 8 days following bare-metal
stent implantation, with the onset ranging from 0 to
639 days. The timing of stent thrombosis was acute in
10 (11%), subacute in 61 (64%), and late in 24 (25%)
patients (Figure 1A and B ). Seventy (74%) patients suffer-
ing from stent thrombosis initially underwent PCI in the
setting of an acute coronary syndrome, as opposed to
25 (26%) patients with an elective indication at the
time of the initial procedure (Table 1 ). The angiographic
baseline characteristics at the time of the initial pro-
cedure are summarized in Table 2. Twenty-two patients
(23%) did not take thienopyridines, and ﬁve patients
took neither ASA nor thienopyridines at the time of
stent thrombosis. Fifty-two (55%) patients were treated
with a statin at the time of stent thrombosis. Patients
suffering from stent thrombosis presented with the diag-
nosis in our institution in 19% of cases, were referred
from another hospital in 65% of cases, and presented on
an outpatient basis in 16% of cases.
Procedural results of emergency PCI for
treatment of stent thrombosis
All 95 patients presenting with stent thrombosis under-
went emergency PCI. The duration of symptom onset
to hospitalization in our institution was 170 min
(median) and the door-to-balloon time was 40 min
(median). Balloon angioplasty was the default treatment
strategy in all (100%) patients, followed by implantation
of another stent in 36 (38%) patients. Glycoprotein IIb/
Figure 1 (A) Incidence of stent thrombosis (n ¼ number of stent thromboses per day) following bare-metal stent implantation. Acute and subacute stent
thrombosis (30 days) are in grey, late stent thrombosis (.30 days) in black. (B) Cumulative incidence of stent thrombosis following bare-metal stent
implantation.
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IIIa (18% tiroﬁban and 42% abciximab) antagonists were
used in 57 (60%) patients, and ﬁbrinolysis was adminis-
tered in eight (8%) patients prior to the procedure.
Thrombotic stent occlusion was complete in 83% and
partial in 17% of patients. Emergency PCI for treatment
of stent thrombosis was successful in 86 (91%) patients.
Reasons for an unsuccessful procedure were an abnor-
mal ﬂow (TIMI 0–2) in nine patients, failure to cross
the occluded stent with a guidewire in eight patients,
and ostial location with inability to pass a guidewire
or balloon in one patient. Angiographic data of emer-
gency PCI for treatment of stent thrombosis are
summarized in Table 3. Procedural major adverse
cardiac events (MACE) consisted of death in two (2%)
and coronary artery bypass grafting in two (2%) patients
after unsuccessful recanalization. Myocardial infarction
occurred in 77 (81%) patients with a peak creatine
kinase level of 1466+ 1570 U/L (CK-MB 220+ 206 U/L).
Eighteen patients did not develop myocardial infarction
owing to an exceedingly short door-to-balloon time of
,20 min in eight patients and a partial but not complete
thrombotic stent occlusion in 16 (17%) patients. Q-wave
myocardial infarction developed in 20 (26%) and non-
Q-wave myocardial infarction in 57 (74%) of these
patients. Left ventricular ejection fraction signiﬁcantly
decreased from 0.54+ 0.15 at the time of the initial
procedure to 0.49+ 0.13 (P, 0.05) at the time of
stent thrombosis. Angiographic analysis revealed a
residual dissection proximal or distal to the stent in 23
(24%) patients as a possible cause for the thrombotic
occlusion.
Clinical follow-up and predictors for adverse
outcome
Clinical outcome at 6 months after emergency PCI for
treatment of stent thrombosis is summarized in Table 4.
The actuarial freedom from cardiac death and MACE is
shown in Figure 2. Multivariable logistic regression analy-
sis identiﬁed the achievement of TIMI 3 ﬂow (OR ¼ 0.1, CI
95% 0.01–0.54, P, 0.001) and diameter stenosis ,50%
(OR ¼ 0.06, CI 95% 0.01–0.32, P , 0.001) during emer-
gency PCI to be independently associated with a
reduced risk of cardiac death (Figure 3 ).
Fifteen (16%) patients suffered from reinfarction after
emergency PCI for stent thrombosis. This was largely
driven by recurrent stent thrombosis of the target
lesion in 11 (73%) patients occurring 5.0+ 8.5 days
(median) after emergency PCI. Logistic regression analy-
sis identiﬁed the omission of abciximab (OR ¼ 4.3, CI 95%
1.1–17.5, P , 0.05) during emergency PCI for stent
thrombosis as the only independent predictor for recur-
rent stent thrombosis.
Table 1 Clinical characteristics of patients undergoing
emergency PCI for treatment of stent thrombosis
95 Patients
Age, mean+ SD 62+ 12
Male gender, n (%) 72 (76)
Hypertension, n (%) 43 (45)
Family history, n (%) 18 (19)
Smoking, n (%) 30 (32)
Dyslipidaemia, n (%) 59 (62)
Diabetes, n (%) 23 (24)
Indication for PCI, n (%)
Elective 25 (26)
Unstable angina 32 (34)
Acute myocardial infarction 38 (40)
Multivessel disease, n (%) 54 (57)
Thienopyridines, n (%)
Ticlopidine 13 (14)
Clopidogrel 82 (86)
Table 2 Angiographic baseline characteristics at the time of
the initial PCI
95 Patients
Lesion type, n (%)
A 5 (6)
B1 23 (24)
B2 44 (46)
C 23 (24)
CTO 4 (4)
Target vessel, n (%)
LAD 57 (60)
LCX 17 (18)
RCA 20 (21)
Left main coronary artery 1 (1)
Quantitative coronary angiography
Diameter stenosis (%) 89+ 12
Lesion length (mm) 12+ 5
MLD (mm) 0.5+ 0.4
RVD (mm) 2.7+ 0.6
Stents
Total stent length (mm), mean+ SD 18.5+ 1.3
Lesion type classiﬁcation according to the ACC/AHA guidelines.37,38
MLD, minimal lumen diameter; RVD, reference vessel diameter; LAD,
left anterior descending artery; RCA, right coronary artery; LCX, left
circumﬂex artery; CTO, chronic total occlusion.
Table 3 Angiographic data of emergency PCI for treatment
of stent thrombosis
Before After P-values
QCA
MLD (mm) 0.17+ 0.47 2.28+ 0.71 ,0.001
RVD (mm) 2.5+ 0.4 2.6+ 0.5 0.07
Diameter stenosis (%) 94+ 16 13+ 21 ,0.001
TIMI ﬂow ,0.001
TIMI ,3 (%) 95 9
TIMI 3 (%) 5 91
LVEF 0.54+ 0.15 0.49+ 0.13 ,0.001
QCA, quantitative coronary angiography; MLD, minimal lumen
diameter; RVD, reference vessel diameter; TIMI, Thrombolysis in
Myocardial Infarction;39 LVEF, left ventricular ejection fraction.
Stent thrombosis 1183
Discussion
The present study summarizes the results of emergency
PCI for the treatment of stent thrombosis in the largest
patient population reported till date. Emergency PCI
was highly effective for recanalization and restoration
of TIMI 3 ﬂow in the infarct-related artery.
Notwithstanding, stent thrombosis was associated with
considerable short- and long-term mortality, an import-
ant risk for recurrent myocardial infarction mainly
driven by recurrent stent thrombosis, and a signiﬁcant
decline of left ventricular ejection fraction. The use of
abciximab was associated with a lower risk for recurrent
stent thrombosis. Of note, stent thrombosis after implan-
tation of bare-metal stents occurred late (.30 days) in
25% of cases.
Procedural outcome of emergency PCI for
treatment of stent thrombosis
Previous studies investigating reperfusion methods for
stent thrombosis showed an unacceptably high failure
rate because of residual thrombus following balloon
angioplasty alone.24 Even supplementary therapy with
intracoronary ﬁbrinolysis showed no clinical beneﬁt.24
In contrast, a small study suggested a beneﬁt of adjunc-
tive therapy with the glycoprotein IIb/IIIa antagonist
abciximab in patients with stent thrombosis resulting in
improved clinical outcome.25 A recent report of a mech-
anical thrombectomy device revealed a high procedural
success rate in a small patient population,26 and the con-
comitant use of glycoprotein IIb/IIIa antagonists was
associated with a lower incidence of the ‘no reﬂow’
phenomenon. These observations are in line with our
study, where emergency PCI for treatment of stent
thrombosis was highly effective in eliminating the throm-
botic occlusion and restoring TIMI 3 ﬂow in .90% of
patients, especially when applied in conjunction with
abciximab.27 In fact, the success rate of emergency PCI
for treatment of stent thrombosis in our study mirrors
the results of primary PCI in the setting of acute myocar-
dial infarction 28 and should therefore be considered as
the therapy of choice in this patient population.
Despite immediate reperfusion therapy by means of
emergency PCI, patients with stent thrombosis developed
a large myocardial infarction (creatine kinase
elevation . 5  ULN) in 37 (39%) cases. Although the
size of myocardial infarction in our study compares
favourably with previous reports29 of infarct size in
patients with stent thrombosis, myocardial infarction
related to stent thrombosis was associated with a signiﬁ-
cant decline in left ventricular function. This ﬁnding
raises concern as left ventricular function has been iden-
tiﬁed as a strong and consistent predictor of long-term
survival following myocardial infarction.30 The signiﬁcant
decline in left ventricular function related to stent
Table 4 Clinical outcome after emergency PCI for stent
thrombosis
95 Patients
Procedural MACE
Death, n (%) 2 (2)
Myocardial infarction, n (%) 77 (81)
Emergency CABG, n (%) 2 (2)
Death, emergency CABG, n (%) 4 (4)
In-hospital MACE (including procedural MACE)
Death, n (%) 7 (7)
Reinfarction, n (%) 4 (4)
TVR, n (%) 4 (4)
Recurrent stent thrombosis, n (%) 4 (4)
6 month MACE (including procedural
and in-hospital MACE)
Death, n (%) 10 (11)
Reinfarction, n (%) 15 (16)
TVR, n (%) 14 (15)
Recurrent stent thrombosis, n (%) 11 (12)
Death, MI, TVR, recurrent ST, n (%) 28 (30)
TVR, target vessel revascularization; MI, myocardial infarction;
CABG, coronary artery bypass grafting. MI denotes an infarction
at the time of stent thrombosis. Reinfarction denotes a recurrent
myocardial infarction after emergency PCI for stent thrombosis.
Figure 2 Actuarial freedom from cardiac death (continuous line) and
MACE (dashed line) during 6 month follow-up.
Figure 3 Predictors of cardiac death after emergency PCI for stent
thrombosis
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thrombosis points to the serious nature of stent thrombo-
sis as a PCI-related adverse event.
Dual antiplatelet therapy consisting of ASA and thieno-
pyridines has been shown to be superior to treatment
with aspirin alone and oral anticoagulation in the preven-
tion of death and non-fatal myocardial infarction follow-
ing coronary stenting.11,16,31 In the era of bare-metal
stents, it has been customary to prescribe dual antiplate-
let therapy for the duration of 1 month followed by the
indeﬁnite treatment with ASA alone. More recently, ran-
domized clinical trials tested the beneﬁt of extended
(9–12 months) dual antiplatelet therapy compared with
treatment with ASA alone. Both the Clopidogrel for the
Reduction of Events During Observation (CREDO) and
PCI-CURE, a prospective substudy of the Clopidogrel in
Unstable angina Recurrent Events trial, revealed a signiﬁ-
cantly reduced risk (27–31% relative risk reduction) of
adverse ischaemic events in favour of an extended dual
antiplatelet regimen following coronary stenting.32,33 In
light of these studies and the observation that one-
quarter of patients in the present study suffered late
(.1 month after PCI) stent thrombosis, extended dual
antiplatelet therapy following coronary stenting should
be considered to prevent ischaemic events. Similarly,
patients who suffered from stent thrombosis are at con-
siderable risk for recurrent stent thrombosis and might
therefore beneﬁt from prolonged (6–12 months) dual
antiplatelet therapy to prevent recurrent ischemic
events.
Prognosis after emergency PCI for stent
thrombosis
The 6 month mortality of 11% following emergency PCI
for stent thrombosis is similar to the 7–9% mortality fol-
lowing primary PCI in the setting of acute myocardial
infarction28 and lower than in previous reports of patients
with stent thrombosis.13,15 Multivariable logistic
regression analysis revealed that the achievement of
TIMI 3 ﬂow during emergency PCI was associated with a
reduced risk of cardiac death. This observation corrobo-
rates angiographic substudies from thrombolytic30 and
primary PCI trials,34 where TIMI 3 ﬂow directly correlated
with improved survival. Accordingly, emergency PCI for
treatment of stent thrombosis should aim beyond the
elimination of the underlying occlusion at restoration of
TIMI 3 ﬂow.
Patients undergoing emergency PCI for stent thrombo-
sis were found at considerable risk for recurrent myocar-
dial infarction. This risk was driven in 75% of patients by
the occurrence of recurrent stent thrombosis. Logistic
regression analysis identiﬁed the omission of abciximab
as a predictor for recurrent stent thrombosis. These
results are in keeping with previous studies reporting an
increased risk of stent thrombosis in patients with
impaired TIMI ﬂow19 and improved outcome with the
use of abciximab.25 The combination of a thrombotic
event and impaired ﬂow highlights the demand for
an aggressive antithrombotic regimen to prevent
future events. Along this line, the use of the glycoprotein
IIb/IIIa antagonist abciximab has been shown to reduce
the incidence of myocardial infarction/stent thrombosis
in the EPISTENT and CAPTURE trials.35,36 Accordingly,
glycoprotein IIb/IIIa antagonists should be strongly
considered as adjunctive pharmacological treatment in
patients undergoing emergency PCI for stent thrombosis
to facilitate achievement of TIMI 3 ﬂow and decrease
the risk of recurrent stent thrombosis.
Limitations
The present study has several limitations. (i) It is a retro-
spective analysis with its inherent shortcomings. (ii)
Silent stent thrombosis or patients with stent thrombosis
not transferred for emergency PCI were not included in
the analysis. Accordingly, a somewhat higher incidence
of stent thrombosis has to be assumed. In addition, the
clinical outcome of patients not immediately transferred
for emergency PCI remains unknown. Notwithstanding,
the focus of the present study was to analyse the pro-
cedural and clinical outcome of patients with stent
thrombosis and to identify predictors of adverse
outcome. (iii) Intravascular ultrasound was not routinely
utilized in patients presenting with stent thrombosis. This
precluded the analysis for mechanical causes of stent
thrombosis such as inappropriate stent expansion and
insufﬁcient stent overlap. (iv) The use of glycoprotein
IIb/IIIa antagonists was left to the discretion of the indi-
vidual operator. The large-scale administration of glyco-
protein IIb/IIIa antagonists commenced only in 1998,
whereas the study population dates back to late 1995.
Selection bias in the use of this medication cannot be
ruled out and might have inﬂuenced the outcome.
Conclusions
Emergency PCI for treatment of stent thrombosis is highly
effective and should be considered as the therapy of
choice in this patient population. Patients undergoing
emergency PCI for stent thrombosis are at risk for
death, recurrent myocardial infarction, and recurrent
stent thrombosis. The achievement of TIMI 3 ﬂow is
associated with a reduced risk of cardiac death following
emergency PCI for treatment of stent thrombosis.
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